title: Antibody persistence after primary vaccination with a hexavalent DTPa-HBV-IPV/HiB vaccine coadministered with a meningococcal C-CRM197 vaccine and response to a DTPa-IPV/HiB booster at 18 months of age.
abstract: Children 17-20 months of age (N = 344) received a diphtheria-tetanus toxoids-acellular pertussis (DTPa)-inactivated poliovirus vaccine (IPV)/Haemophilus influenzae (Hib) booster after a 3-dose primary vaccination course with DTPa-hepatitis B vaccine-IPV/Hib plus conjugate meningococcal C vaccine-CRM. Seroprotection rates were >80% (diphtheria, tetanus, hepatitis B, polio and polyribosylribitol phosphate) before and > or =96.6% (diphtheria, tetanus, polio and polyribosylribitol phosphate) after booster vaccination. The booster was well-tolerated (fever >39.5 degrees C after <2% of doses; large swelling reactions after 6.3% of doses).
authors.affiliation: Hospital de Móstoles, Madrid, Spain.
authors.forename: Juan-Carlos
authors.initials: JC
authors.lastname: Tejedor
authors.forename: Félix
authors.initials: F
authors.lastname: Omeñaca
authors.forename: José
authors.initials: J
authors.lastname: García-Sicilia
authors.forename: Carlos
authors.initials: C
authors.lastname: Esporrín
authors.forename: Vicente
authors.initials: V
authors.lastname: Molina
authors.forename: Josep
authors.initials: J
authors.lastname: Marés
authors.forename: Marta
authors.initials: M
authors.lastname: Muro
authors.forename: Pilar
authors.initials: P
authors.lastname: Sanjuan
authors.forename: María
authors.initials: M
authors.lastname: Méndez
authors.forename: Roser
authors.initials: R
authors.lastname: Teixidor
authors.forename: Manuel
authors.initials: M
authors.lastname: Enrubia
authors.forename: Pilar
authors.initials: P
authors.lastname: García-Corbeira
authors.forename: Reyes
authors.initials: R
authors.lastname: Boceta
authors.forename: Jeanne-Marie
authors.initials: JM
authors.lastname: Jacquet
authors.forename: Lode
authors.initials: L
authors.lastname: Schuerman
mesh_terms: D000276:Adjuvants, Immunologic; D000907:Antibodies, Bacterial / Q000097:blood; D000914:Antibodies, Viral / Q000097:blood; D001426:Bacterial Proteins / Q000008:administration & dosage / Q000276:immunology*; D015721:Diphtheria-Tetanus-Pertussis Vaccine; D005260:Female; D017325:Hepatitis B Vaccines / Q000008:administration & dosage / Q000276:immunology*; D006801:Humans; D007117:Immunization, Secondary; D007223:Infant; D008297:Male; D022401:Meningococcal Vaccines / Q000008:administration & dosage / Q000276:immunology*; D011054:Poliovirus Vaccine, Inactivated; D014611:Vaccination; D017778:Vaccines, Combined / Q000008:administration & dosage / Q000276:immunology*
chemical_list: D000276:Adjuvants, Immunologic; D000907:Antibodies, Bacterial; D000914:Antibodies, Viral; D001426:Bacterial Proteins; C500334:DT5aP-Hib-IPV vaccine; D015721:Diphtheria-Tetanus-Pertussis Vaccine; D017325:Hepatitis B Vaccines; D022401:Meningococcal Vaccines; D011054:Poliovirus Vaccine, Inactivated; D017778:Vaccines, Combined; C410218:serogroup C meningococcal conjugate vaccine; C028581:CRM197 (non-toxic variant of diphtheria toxin)